BRUKER CORP

Listed Company

BRKRCIK 0001109354NasdaqLarge AcceleratedLaboratory Analytical InstrumentsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$3.44B

Net Income

$-8.60M

Total Assets

$6.24B

Equity

$2.46B

Shares Out

152.14M

Op. Cash Flow

$134.10M

Business

BRUKER CORP develops, manufactures and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable exploration of life and materials at microscopic, molecular and cellular levels. Its main products and services include magnetic resonance, mass spectrometry, chromatography, X-ray, microscopy, metrology, molecular spectroscopy systems, preclinical and clinical imaging, lab automation, software, consumables and services for analysis, diagnostics and lifecycle support. The company operates four reportable segments: BSI BioSpin, BSI CALID, BSI NANO and Bruker Energy & Supercon Technologies (BEST). It sells globally through direct sales forces and distributors across North America, Europe, Asia Pacific and other international markets.

Summary from filing dated 2025-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	3,437	3,366	2,965	2,531	2,418
Total cost of revenue	1,859	1,717	1,451	1,225	1,208
Gross profit	1,578	1,650	1,513	1,306	1,210
Selling, general and administrative	947	894	729	607	561
Research and development	395	377	295	236	221
Goodwill impairment charge	97	0	0	—	—
Other charges, net	71	126	52	—	—
Total operating expenses	1,510	1,396	1,076	873	796
Operating income	68	253	437	433	413
Bargain purchase gain and associated measurement period adjustments	0	−8	144	0	—
Interest and other expense, net	−46	−38	−37	−19	−20
Income before income taxes, equity in (losses) income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries	22	207	544	414	394
Income tax provision	29	91	118	116	113
Equity in (losses) income of unconsolidated investees, net of tax	−1	−2	2	1	—
Consolidated net (loss) income	−8	114	429	299	281
Net income attributable to noncontrolling interests in consolidated subsidiaries	300,000	700,000	1	2	4
Net (loss) income attributable to Bruker Corporation	−9	113	427	297	277
Dividends on Series A Mandatory Convertible Preferred Stock	14	0	0	—	—
Net (loss) income attributable to Bruker Corporation common shareholders	−23	113	427	—	—
Basic (per share)	−0.15	0.76	2.92	2	1.83
Diluted (per share)	−0.15	0.76	2.9	1.99	1.81
Basic (shares)	152	149	146	148.6	151.4
Diluted (shares)	152	150	147	149.4	152.9

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	299	183	488	646	1,068
Accounts receivable, net	545	566	492	473	417
Inventories	1,095	1,068	968	800	710
Other current assets	274	237	216	194	172
Total current assets	2,213	2,053	2,164	2,113	2,472
Property, plant and equipment, net	745	669	600	487	406
Goodwill	1,548	1,507	583	458	340
Intangible assets, net	900	913	331	271	212
Operating lease assets	166	146	92	51	60
Deferred tax assets, net	422	286	297	77	90
Other long-term assets	249	233	184	155	71
Total assets	6,241	5,807	4,250	3,612	3,650
Current portion of long-term debt and finance lease obligations	17	33	121	19	112
Accounts payable	216	234	203	178	147
Current portion of deferred revenue and customer advances	441	438	—	218	198
Other current liabilities	605	577	478	347	481
Total current liabilities	1,279	1,281	1,202	914	939
Long-term debt	1,853	2,062	1,160	1,201	1,222
Long-term deferred revenue and customer advances	109	100	92	102	50
Deferred tax liabilities	113	119	68	62	46
Operating lease liabilities	139	119	75	35	42
Other long-term liabilities	239	311	240	121	162
Total liabilities	3,731	3,992	2,837	2,480	—
Commitments and contingencies (note 25)	—	—	—	—	—
Redeemable noncontrolling interests	37	18	19	6	200,000
Common stock, par value $0.01; Authorized - 260,000,000 shares Issued - 183,047,629 shares (2024: 182,456,831); Outstanding - 152,143,041 shares (2024: 151,677,952)	2	2	—	—	—
Treasury stock, at cost Purchased - 30,904,588 shares (2024: 30,778,879)	−1,242	−1,237	−1,237	−1,085	−820
Additional paid-in capital	1,415	713	283	256	238
Retained earnings	2,362	2,407	2,324	1,926	1,660
Accumulated other comprehensive loss, net of tax	−80	−104	6	15	−8
Total shareholders' equity attributable to Bruker Corporation	2,457	1,781	1,377	1,114	1,071
Noncontrolling interests in consolidated subsidiaries	17	16	17	12	14
Total shareholders' equity	2,474	1,797	1,395	1,126	1,085
Total liabilities, redeemable noncontrolling interests and shareholders' equity	6,241	5,807	4,250	3,612	3,650

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	220	184	115	89	89
Stock-based compensation expense	20	25	31	28	17
Deferred income taxes	−105	−64	−24	−15	−6
Impairment of goodwill, intangible assets, other long-lived assets, and certain minority investments	152	29	22	—	—
Write down of inventories	76	60	19	—	—
Acquisition-related hybrid liability adjustments	−49	20	−7	—	—
Foreign currency transaction (gain) loss, net	−56	−28	19	—	—
Other non-cash expenses, net	28	22	−21	27	28
Accounts receivable	54	−41	−900,000	−68	−95
Inventories	12	−70	−125	−138	−67
Accounts payable	−38	21	1	33	—
Accrued compensation	−27	15	22	—	—
Income taxes payable, net	−94	−15	44	−7	−44
Deferred revenue and customer advances	−23	−53	−600,000	53	39
Other changes in operating assets and liabilities, net	−30	24	−28	−18	−19
Net cash provided by operating activities	134	251	350	274	282
Purchases of property, plant and equipment	−91	−115	−107	−129	−92
Cash paid for minority investments	−7	−48	−25	−60	−500,000
Cash paid for business combinations, net of cash acquired	−74	−1,600	−227	−182	−65
Cash paid for in-process research and development and related assets	−29	0	0	—	—
Other investing activities, net	5	6	32	—	—
Net cash used in investing activities	−197	−1,757	−326	−252	−192
Repayments of revolving lines of credit	−779	−1,213	0	0	0
Proceeds from revolving lines of credit	751	1,250	0	0	0
Repayment of long-term debt	−467	−135	−24	−111	−800,000
Proceeds from long-term debt	4	974	2	300,000	493
Proceeds from issuance of Series A Mandatory Convertible Preferred Stock, net of issuance costs	670	0	0	—	—
Proceeds from issuance of common stock, net	8	409	10	3	7
Payment of dividends to Series A Mandatory Convertible Preferred Shareholders	−10	0	0	—	—
Payment of dividends to common shareholders	−23	−30	−29	−30	−24
Repurchase of common stock	−10	0	−152	−263	−153
Other financing activities, net	−8	−25	300,000	—	—
Net cash provided by (used in) financing activities	135	1,230	−193	−415	319
Effect of exchange rate changes on cash, cash equivalents and restricted cash	44	−29	12	−31	−23
Net change in cash, cash equivalents and restricted cash	116	−305	−157	−423	386
Cash paid for interest	71	55	34	24	20
Cash paid for taxes	223	154	97	147	146

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro